ORPP logo
Image from Google Jackets

False Hope : Bone Marrow Transplantation for Breast Cancer.

By: Contributor(s): Material type: TextTextPublisher: Oxford : Oxford University Press, Incorporated, 2007Copyright date: ©2007Edition: 1st edDescription: 1 online resource (368 pages)Content type:
  • text
Media type:
  • computer
Carrier type:
  • online resource
ISBN:
  • 9780199748242
Subject(s): Genre/Form: Additional physical formats: Print version:: False HopeDDC classification:
  • 616.99/449061
LOC classification:
  • RC280.B8F353 2007
Online resources:
Contents:
Intro -- Contents -- Introduction -- Part I: Initial Conditions -- 1. Breast Cancer Patients and the Emergence of a Treatment -- 2. Jumping the Gun -- Part II: Drivers of Clinical Use -- 3. Court Trials -- 4. Litigation Strategies -- 5. Entrepreneurial Oncology -- 6. Government Mandates -- Part III: The Struggle for Evidence-Based Medicine -- 7. Technology Assessments -- 8. Clinical Trials -- 9. Dénouement -- Part IV: The Significance of the Story -- 10. Values in Conflict -- Appendix: Evidence-Based Reviews of Clinical Trials -- Notes -- References -- Index -- A -- B -- C -- D -- E -- F -- G -- H -- I -- J -- K -- L -- M -- N -- O -- P -- Q -- R -- S -- T -- U -- V -- W -- Y -- Z.
Summary: In the late 1980s, a promising new treatment for breast cancer emerged: high-dose chemotherapy with autologous bone marrow transplantation or HDC/ABMT. By the 1990s, it had burst upon the oncology scene and disseminated rapidly before having been carefully evaluated. By the time published studies showed that the procedure was ineffective, more than 30,000 women had received the treatment, shortening their lives and adding to their suffering. This book tells of the rise and demise of HDC/ABMT for metastatic and early stage breast cancer, and fully explores the story's implications, which go well beyond the immediate procedure, and beyond breast cancer, to how we in the United States evaluate other medical procedures, especially life-saving ones.
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
No physical items for this record

Intro -- Contents -- Introduction -- Part I: Initial Conditions -- 1. Breast Cancer Patients and the Emergence of a Treatment -- 2. Jumping the Gun -- Part II: Drivers of Clinical Use -- 3. Court Trials -- 4. Litigation Strategies -- 5. Entrepreneurial Oncology -- 6. Government Mandates -- Part III: The Struggle for Evidence-Based Medicine -- 7. Technology Assessments -- 8. Clinical Trials -- 9. Dénouement -- Part IV: The Significance of the Story -- 10. Values in Conflict -- Appendix: Evidence-Based Reviews of Clinical Trials -- Notes -- References -- Index -- A -- B -- C -- D -- E -- F -- G -- H -- I -- J -- K -- L -- M -- N -- O -- P -- Q -- R -- S -- T -- U -- V -- W -- Y -- Z.

In the late 1980s, a promising new treatment for breast cancer emerged: high-dose chemotherapy with autologous bone marrow transplantation or HDC/ABMT. By the 1990s, it had burst upon the oncology scene and disseminated rapidly before having been carefully evaluated. By the time published studies showed that the procedure was ineffective, more than 30,000 women had received the treatment, shortening their lives and adding to their suffering. This book tells of the rise and demise of HDC/ABMT for metastatic and early stage breast cancer, and fully explores the story's implications, which go well beyond the immediate procedure, and beyond breast cancer, to how we in the United States evaluate other medical procedures, especially life-saving ones.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.

There are no comments on this title.

to post a comment.

© 2024 Resource Centre. All rights reserved.